Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Work In Process (2022 - 2025)

Historic Work In Process for InMed Pharmaceuticals (INM) over the last 4 years, with Q3 2025 value amounting to $422798.0.

  • InMed Pharmaceuticals' Work In Process rose 219208.5% to $422798.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $422798.0, marking a year-over-year increase of 219208.5%. This contributed to the annual value of $26695.0 for FY2025, which is 1337.57% down from last year.
  • InMed Pharmaceuticals' Work In Process amounted to $422798.0 in Q3 2025, which was up 219208.5% from $26695.0 recorded in Q2 2025.
  • InMed Pharmaceuticals' 5-year Work In Process high stood at $1.7 million for Q2 2022, and its period low was $18446.0 during Q3 2024.
  • Over the past 4 years, InMed Pharmaceuticals' median Work In Process value was $323714.0 (recorded in 2025), while the average stood at $413581.0.
  • Per our database at Business Quant, InMed Pharmaceuticals' Work In Process tumbled by 9400.58% in 2024 and then surged by 219208.5% in 2025.
  • Over the past 4 years, InMed Pharmaceuticals' Work In Process (Quarter) stood at $798813.0 in 2022, then tumbled by 76.59% to $186980.0 in 2023, then soared by 36.91% to $255992.0 in 2024, then surged by 65.16% to $422798.0 in 2025.
  • Its last three reported values are $422798.0 in Q3 2025, $26695.0 for Q2 2025, and $323714.0 during Q1 2025.